Browse > Article
http://dx.doi.org/10.4014/jmb.0906.06018

Nationwide Surveillance Study of Vancomycin-Intermediate Staphylococcus aureus Strains in Korean Hospitals from 2001 to 2006  

Chung, Gyung-Tae (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Cha, Jeong-Ok (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Han, Sun-Young (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Jang, Hee-Sun (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Lee, Kyeong-Min (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Yoo, Jae-Il (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Yoo, Jeong-Sik (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Kim, Hong-Bin (Department of Internal Medicine, Seoul National University College of Medicine)
Eun, Soo-Hoon (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Kim, Bong-Su (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Park, Ok (Infectious Disease Surveillance Team, Korea Center for Disease Control and Prevention)
Lee, Yeong-Seon (Division of Antimicrobial Resistance, Center for Infectious Disease, National Institute of Health)
Publication Information
Journal of Microbiology and Biotechnology / v.20, no.3, 2010 , pp. 637-642 More about this Journal
Abstract
We investigated the prevalence and the molecular characteristics of vancomycin-intermediate Staphylococcus aureus (VISA) among methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from clinical samples at tertiary or general hospitals participating in a nationwide surveillance program for VISA and vancomycin-resistant Staphylococcus aureus (VRSA) in Korea during an 8-week period in each year from 2001 to 2006. Of 41,639 MRSAs isolated, 37,856 were screened and 169 grew on brain heart infusion agar supplemented with 4 ${\mu}g/ml$ vancomycin. A vancomycin MIC of 4 ${\mu}g/ml$ was confirmed for 33 VISA isolates of the 169 isolates. Eighteen of the 33 isolates were classified as hetero-VISA (hVISA) by the population analysis profile (PAP) method. All VISA isolates were susceptible to linezolid, tigecycline, and quinupristin-dalfopristin. Most VISA isolates (MIC 4 ${\mu}g/ml$) showed a PFGE C pattern with sec, seg, and sei enterotoxin genes, including ST5-SCCmec type II, or a PFGE A pattern with sea, including ST239-SCCmec type III.
Keywords
Staphylococcus aureus; surveillance; vancomycin-intermediate;
Citations & Related Records

Times Cited By Web Of Science : 7  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Goldstein, F. 2007. The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 59: 1-4.
2 Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oquri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40: 135-136.   DOI
3 Kim, M. N., S. H. Hwang, Y. J. Pyo, H. M. Mun, and C. H. Pai. 2002. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J. Clin. Microbiol. 40: 1376-1380.   DOI   ScienceOn
4 Marchese, A., G. Balistreri, E. Tonoli, E. A. Debbla, and G. C. Schito. 2000. Heterogeneous vancomycin resistance in methicillinresistant Staphylococcus aureus strains in a large Italian hospital. J. Clin. Microbiol. 38: 866-869.
5 Poly, M. C., C. Grelaud, C. Martin, L. de Lumley, and F. Denis. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351: 1212.
6 Clark, N. C., R. C. Cooksey, B. C. Hill, J. M. Swenson, and F. C. Tenover. 1993. Characterization of glycopeptides-resistant enterococci from U.S. hospitals. Antimicrob. Agents Chemother. 37: 2311-2317.   DOI   ScienceOn
7 Denis, O., C. Nonhoff, B. Byl, C. Knoop, S. Bobin-Dubreux, and M. J. Struelens. 2002. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: Microbiological and clinical features. J. Antimicrob. Chemother. 50: 383-391.   DOI
8 Guerin, F., A. Buu-Hoi, J. L. Mainardi, G. Kac, N. Colardelle, S. Vaupre, L. Gutmann, and I. Podglajen. 2000. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J. Clin. Microbiol. 38: 2985-2988.
9 Hussain, F. M., S. Boyle-Vavra, P. B. Shete, and R. S. Daum. 2002. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J. Infect. Dis. 186: 661-667.   DOI   ScienceOn
10 Kim, H. B., Y. S. Lee, B. S. Kim, J. O. Cha, S. U. Kwon, H. J. Lee, et al. 2006. Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 microg/ml Korea. Microb. Drug Res. 12: 33-38.   DOI   ScienceOn
11 Monday, S. R. and G. A. Bohach. 1999. Use of multiplex PCR to detect classical and newly described pyrogenic toxin genes in staphylococcal isolates. J. Clin. Microbiol. 37: 3411-3414.
12 Reverdy, M. E., S. Jarraud, S. Bobin-Dubreux, E. Burel, P. Girardo, G. Lina, F. Vandenesch, and J. Etienne. 2001. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals. Clin. Microbiol. Infect. 7: 267-272.   DOI   ScienceOn
13 Sieradzki, K., R. B. Roberts, S. W. Harber, and A. Tomasz. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340: 517-523.   DOI   ScienceOn
14 Lee, K., C. L. Chang, N. Y. Lee, H. S. Kim, K. S. Hong, and H. C. Cho. 2000. Korean nationwide surveillance of antimicrobial resistance of bacteria in 1998. Yonsei Med. J. 41: 497-506.
15 Van Griethuysen, A., A. Van't Veen, A. Buiting, T. Walsh, and J. Kluytmans. 2003. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J. Clin. Microbiol. 41: 2487-2491.   DOI   ScienceOn
16 Aligholi, M., M. Emaneini, F. Jabalameli, S. Shahsavan, H. Dabiri, and H. Sedaght. 2008. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini hospital in Tahran. Med. Princ. Pract. 17: 432-434.   DOI   ScienceOn
17 Bierbaum, G., K. Fuchs, W. Lenz, C. Szekat, and H. G. Sahl. 1999. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur. J. Clin. Microbiol. Infect. Dis. 18: 691-696.   DOI   ScienceOn
18 Centers for Diseases Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin - United States. MMWR 51: 565-567.
19 Oliveira, D. C. and H. de Lencastre. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 2155-2161.   DOI   ScienceOn
20 Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 1079-1082.   DOI   ScienceOn
21 Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J. Clin. Microbiol. 33: 2233-2239.
22 Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a U.K. hospital. J. Antimicrob. Chemother. 47: 399-403.   DOI
23 Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350: 1670-1673.   DOI   ScienceOn
24 Kim, M. N., C. H. Pai, J. H. Woo, J. S. Ryu, and K. Hiramatsu. 2000. Vancomycin-intermediate Staphylococcus aureus in Korea. J. Clin. Microbiol. 38: 3879-3881.
25 Lulitanond, A., C. Engchanil, P. Chaimanee, M. Vorachit, T. Ito, and H. Keiichi. 2009. The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand. J. Clin. Microbiol. 47: 2311-2316.   DOI   ScienceOn
26 Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, et al. 1999. Emergence of Vancomycin Resistance in Staphylococcus aureus Working Group. N. Engl. J. Med. 340: 493-501.   DOI   ScienceOn
27 Roberts, J., R. Bismuth, and V. Jarlier. 2006. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: A 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57: 506-510.   DOI   ScienceOn
28 Ike, Y., Y. Arakawa, X. Ma, K. Tatewaki, M. Nagasawa, H. Tomita, K. Tanimoto, and S. Fujimoto. 2001. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J. Clin. Microbiol. 39: 4445-4451.   DOI   ScienceOn
29 Centers for Diseases Control and Prevention. 1999. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois. MMWR 48: 1165-1167.
30 Rybak, M. J., S. N. Leonard, K. L. Rossi, C. M. Cheung, H. S. Sadar, and R. N. Jones. 2008. Characterization of vancomycinheteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46: 2950-2954.   DOI   ScienceOn
31 Hanaki, H., Y. Hososaka, C. Yanagisawa, Y. Otsuka, Z. Nagasawa, T. Nakae, and K. Sunakawa. 2007. Occurrence of vancomycinintermediate-resistant Staphylococcus aureus in Japan. J. Infect. Chemother. 13: 118-121.   DOI   ScienceOn
32 Finks, J., E. Wells, T. L. Dyke, N. Husain, L. Plizga, R. Heddurshetti, et al. 2009. Vancomycin-resistant Staphylococcus aureus, Michigan, U.S.A., 2007. Emerg. Infect. Dis. 15: 943-945.   DOI
33 Saha, B., A. K. Singh, A. Ghosh, and M. Bal. 2008. Identification and characterization of vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J. Med. Microbiol. 57: 72-79.   DOI   ScienceOn
34 Wong, S. S. Y., P. L. Ho, P. C. Y. Woo, and K. Y. Yuen. 1999. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin. Infect. Dis. 29: 760-767.   DOI   ScienceOn
35 Becker, K., R. Roth, and G. Peters. 1998. Rapid and specific detection of toxigenic Staphylococcus aureus: Use of two multiplex PCR enzyme immunoassays for amplification and hybridization of staphylococcal enterotoxin genes, exfoliative toxin genes, and toxic shock syndrome toxin 1 gene. J. Clin. Microbiol. 36: 2548-2553.
36 Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard 7th Ed. Document M7-A7. CLSI, Wayne, PA.
37 Moore, M. R., F. Perdreau-Remington, and H. F. Chambers. 2003. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47: 1262-1266.   DOI   ScienceOn
38 Tiwari, H. K. and M. R. Sen. 2006. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect. Dis. 6: 156-161.   DOI   ScienceOn